Carla Leal Moreira

Carla Leal Moreira

Auto-generated profile, based on publicly available information

Carla Leal Moreira

Nephrology Department, Centro Hospitalar Universitário do Porto, Hospital Geral de Santo António, Porto, Portugal

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Case Reports in Endocrinology
Verified
Journal Article
Open access
PDF file
VSVania Benido Silva
Vania Benido Silva
MPMaria Teresa Pereira
Maria Teresa Pereira
CMCarla Leal Moreira
Carla Leal Moreira
SMSílvia Santos Monteiro
Sílvia Santos Monteiro
IIIsabel Inácio
Isabel Inácio
MCMaria Helena Cardoso
Maria Helena Cardoso
Nephrotic syndrome may trigger the onset of hypothyroidism, promoting massive urinary protein losses including thyroxine (T4) and triiodothyronine (T3) along with their binding proteins. At an early stage, a clinical and biochemical euthyroid state is expected. However, in patients with prolonged and severe proteinuria, especially with concomitant low thyroid reserve, urinary losses of free and protein‐bound thyroid hormones are sufficiently pronounced to induce a subclinical or overt hypothyroidism. Despite its high prevalence in clinical practice, the literature lacks case reports of newly diagnosed clinical hypothyroidism due to NS in adults, making this condition under‐recognized. We report a case of a 23‐year‐old man with previous normal thyroid function who developed overt hypothyroidism due to a severe nephrotic syndrome, requiring supplementation with levothyroxine (LT). After the patient had undergone bilateral nephrectomy, treatment with LT was discontinued and thyroid function normalized.

7 August 2018 in Nefrología
Verified
Journal Article
Open access
PDF file
CMCarla L. Moreira
Carla L. Moreira
JRJoana Rocha
Joana Rocha
MFMargarida Ferreira-Silva
Margarida Ferreira-Silva
JSJoana Delgado Silva
Joana Delgado Silva
MAManuela Barbosa Almeida
Manuela Barbosa Almeida
ACAntónio Cabrita
António Cabrita

16 March 2017 in Amyloid
Verified
Journal Article
Closed access
CMCarla Leal Moreira
Carla Leal Moreira
ARAna Rocha
Ana Rocha
JSJosefina Santos
Josefina Santos
MSMarta Santos
Marta Santos
IBIdalina Beirão
Idalina Beirão
LLLobato Luisa
Lobato Luisa
(2017). The ever-growing understanding of transthyretin amyloidosis nephropathy. Amyloid: Vol. 24, PROCEEDINGS OF THE XVth INTERNATIONAL SYMPOSIUM ON AMYLOIDOSIS, pp. 117-118.

1 January 2019 in Nefrología (English Edition)
Verified
Journal Article
Open access
PDF file
CMCarla L. Moreira
Carla L. Moreira
JRJoana Rocha
Joana Rocha
MSMargarida Silva
Margarida Silva
JSJoana Silva
Joana Silva
MAManuela Almeida
Manuela Almeida
ACAntónio Cabrita
António Cabrita

1 February 2019 in Hemodialysis International
Verified
Journal Article
Closed access
PDF file
CMCarla Leal Moreira
Carla Leal Moreira
ACAna Castro
Ana Castro
FSFernanda Silva
Fernanda Silva
PAPaulo Almeida
Paulo Almeida
AMAntónio Nórton de Matos
António Nórton de Matos
JQJosé Alexandre Queirós
José Alexandre Queirós

7 October 2020 in Transplantation
Verified
Journal Article
Closed access
CMCarla Leal Moreira
Carla Leal Moreira
MSM. Hasib Mbbs Sidiqi
M. Hasib Mbbs Sidiqi
FBFrancis K. Buadi
Francis K. Buadi
MLMark R. Litzow
Mark R. Litzow
MGMorie A. Gertz
Morie A. Gertz
NLNelson Leung
Nelson Leung
Background.: Experience with sequential hematopoietic stem cell transplant (HSCT) and kidney transplant (KT) is limited. Methods.: We conducted a retrospective observational study of adult patients who underwent both HSCT and KT at our center, with a median follow-up of 11 y. Results.: In our 54 patients cohort (94% autologous HSCT), 36 (67%) patients received HSCT first followed by KT, while 18 (33%) received KT before HSCT. In both groups, AL amyloidosis represented 50% of hematologic diagnosis. Only 4 patients expired due to hematologic disease relapse (2 patients in each group) and only 3 allografts were lost due to hematologic disease recurrence (HSCT first n = 1 and KT first n = 2). Overall 1, 5, and 10 y death-censored graft survival rates were 94%, 94%, and 94%, respectively, for the HSCT first group and 89%, 89%, and 75%, respectively, for the KT first group. Overall 1, 5, and 10 y patients survival rates were 100%, 97% and 90%, respectively, for the HSCT first group and 100%, 76%, and 63%, respectively, for the KT first group. Conclusions.: Our study supports safety of sequential KT and HSCT, with improved overall patient survival compared to recipients of HSCT remaining on dialysis and good long-term kidney allograft outcome.